18F-FDG Pet-Guided External Beam Radiotherapy in Iodine-Refractory Differentiated Thyroid Cancer: A Pilot Study
Open Access
- 19 October 2017
- journal article
- research article
- Published by Wiley in Journal of Thyroid Research
- Vol. 2017, 1-9
Abstract
Introduction. To evaluate the clinical response rate after a postoperative 18F-FDG PET/CT guided external beam radiotherapy (EBRT) in Iodine-refractory differentiated thyroid cancer. Material and Methods. Patients with thyroid cancer locally recurrent after total thyroidectomy plus metabolic radiotherapy and treated with radical EBRT were included. Inclusion criteria were detectable thyroglobulin (Tg), negative postmetabolic radiotherapy whole body scintigraphy, and no surgical indications. The pretreatment 18F-FDG PET/CT resulted positive in all cases (loggia, lymph nodes, and lung). EBRT was delivered with IMRT-SIB technique. A 18F-FDG PET/CT revaluation and Tg dosage were performed 3 months after the treatment. Results. Sixteen consecutive patients were included in this analysis (median follow-up: 6–44 months). Post-EBRT 18F-FDG PET/CT showed CR in 43.7%, PR in 31.2%, SD in 25.0% patients, and PD due to lung metastases in 12.5%. Overall response rate was 75.0% (CI 95%: 41.4–93.3%). Tg levels decreased in 75.0% with a median Δ of 68.0%. Two-year PFS and OS rates were 80.0% and 93.0%, respectively. Acute G3 toxicity occurred in 18.7% and late G2 toxicity in 12.5%. Conclusions. 18F-FDG PET/CT was useful in target definition for radiotherapy planning, identifying positive areas not detected with 131I scintigraphy. IMRT based EBRT was feasible and our results encourage future prospective studies. This clinical trial is registered with ID: NCT03191643.Keywords
This publication has 22 references indexed in Scilit:
- Prognostic Significance of FDG PET/CT on the Follow-Up of Patients of Differentiated Thyroid Carcinoma With Negative 131I Whole-Body Scan and Elevated Thyroglobulin LevelsClinical Nuclear Medicine, 2012
- Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive DiseaseJournal of Thyroid Research, 2012
- The effect of external beam radiotherapy volume on locoregional control in patients with locoregionally advanced or recurrent nonanaplastic thyroid cancerRadiation Oncology, 2010
- Differentiated Thyroid Cancer with Extrathyroidal Extension: Prognosis and the Role of External Beam RadiotherapyJournal of Thyroid Research, 2010
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- The role of external beam radiotherapy in the treatment of papillary thyroid cancerEndocrine-Related Cancer, 2006
- Respective Roles of Thyroglobulin, Radioiodine Imaging, and Positron Emission Tomography in the Assessment of Thyroid CancerSeminars in Nuclear Medicine, 2006
- Current Approaches to Primary Therapy for Papillary and Follicular Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2001
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden HospitalEuropean Journal of Cancer, 1994